The peripheral neuropathy market is expanding as diabetes prevalence, population ageing, cancer survival, and awareness of nerve disorders increase globally. The market was valued at USD 2.52 billion in 2024 and is projected to reach USD 6.51 billion by 2035, growing at a CAGR of 9.01%. 1158

Peripheral neuropathy occurs when nerves outside the brain and spinal cord are damaged or dysfunctional. Symptoms can include numbness, burning sensations, tingling, weakness, sensitivity to touch, and persistent pain. Causes vary and can include diabetes, chemotherapy, vitamin deficiencies, autoimmune disorders, infections, inherited conditions, and trauma.

Diabetic peripheral neuropathy is the largest market segment, representing approximately 49% of demand. As diabetes affects more people worldwide, healthcare providers are placing greater focus on early detection, blood-glucose management, foot care, pain relief, and long-term monitoring.

Pharmacological therapies remain the largest treatment category, while non-pharmacological approaches are growing rapidly. Physical therapy, transcutaneous electrical nerve stimulation, lifestyle support, psychological care, and multidisciplinary pain-management programs may be used as part of individualized treatment plans.

Read more: Peripheral Neuropathy Market 1158

FAQs

Q1. What is peripheral neuropathy?
It is nerve damage affecting the peripheral nervous system, which can cause pain, tingling, numbness, weakness, or altered sensation.

Q2. Which type leads the market?
Diabetic peripheral neuropathy leads because diabetes is one of the most common causes of nerve damage.

Tags: peripheral neuropathy market, diabetic neuropathy, nerve pain treatment, chronic pain management, diabetes complications